Status:
COMPLETED
First-in-Human Single Ascending and Multiple Dose of GLPG0634
Lead Sponsor:
Galapagos NV
Conditions:
Healthy
Eligibility:
MALE
40-60 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral doses of GLPG0634 compared to placebo (with and without food). Also, pharmacokinet...
Eligibility Criteria
Inclusion
- healthy male, age 40-60 years
- body mass index (BMI) between 18-30 kg/m², inclusive.
Exclusion
- any condition that might interfere with the procedures or tests in the study
- smoking
- drug or alcohol abuse
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01179581
Start Date
August 1 2010
End Date
March 1 2011
Last Update
March 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SGS Stuivenberg
Antwerp, Belgium